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Abstract
FTDP-17 mutations in the tau gene lead to early-onset frontotemporal dementias characterized by
the pathological aggregation of the microtubule-associated protein tau. Tau aggregation is closely
correlated with the progression and severity of localized atrophy of certain regions in the brain.
These mutations are primarily located in or near the microtubule-binding repeat regions of tau and
can have vastly different effects on the protein. Some mutations have been linked to effects such
as increased aggregation, hyperphosphorylation, defects in mRNA splicing, and decreased
interaction with microtubules. Given the differential effects of the mutations it may not be
surprising that the pathology associated with FTDP-17 can vary widely as well. Despite this
variety, several of the mutations are commonly used interchangeably as aggregation inducers for
in vitro and in vivo models of tauopathies. We generated recombinant forms of 12 FTDP-17
mutations chosen for their predicted effects on the charge, hydrophobicity, and secondary
structure of the protein. We then examined the effects that the mutations had on the properties of
in vitro aggregation of the protein and its ability to stabilize microtubule assembly. The group of
mutations induced very different effects on the total amount of aggregation, the kinetics of
aggregation, and filament morphology. Several of the mutations inhibited the microtubule-
stabilization ability of tau while others had very little effect compared to wild-type tau. These
results indicate that the mechanisms of disease progression may differ among FTDP-17 mutations
and that the effects of the varying mutations may not be equal in all model systems.
Tauopathies are a group of neurodegenerative disorders characterized by the pathological
aggregation of the microtubule-associated protein tau. Although tau can be found in a
variety of tissues, it is predominantly found in neurons where its primary functions are to
promote the assembly and stability of microtubules in addition to interacting with cellular
membranes and playing a role in regulation of microtubule spacing as well as axonal
transport (1–5). The tau gene contains sixteen exons that, in the central nervous system, give
rise to six distinct isoforms that differ by their pattern of inclusion or exclusion of exons 2, 3
and 10. Exon 10 encodes one of four potential microtubule-binding repeat regions (MTBR)
that are the primary source of tau interactions with microtubules. Each MTBR contains a
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highly-conserved 18 amino acid repeat and an inter-repeat regions of 13 or 14 amino acids,
both of which make significant contributions microtubule binding (6–8).
Tau MTBR were found to comprise the core of pathologically aggregated tau filaments (9)
and have been found to be necessary and sufficient for tau aggregation into straight and
paired-helical filaments (10, 11). Within the MTBR, the sequences 275VQIINK in exon 10
and 306VQIVYK in exon 11 misfold into β-strands that subsequently interact with adjacent
tau molecules to form characteristic amyloid structure (11–15). The nucleation step,
formation of oligomers, is likely the first step in tau aggregation and can be followed by a
slower elongation phase that leads to the formation of longer straight or paired helical
filaments from these oligomers (16, 17). Aggregated tau then accumulates in pathological
structures such as neurofibrillary tangles, neuropil threads, Pick bodies and others that
correlate with the type and severity of clinical impairment in neurodegenerative tauopathies
(reviewed in (18, 19)).
In Alzheimer’s disease and other related tauopathies, tau aggregation is oftentimes
associated with other pathological structures such as beta-amyloid extracellular senile
plaques. It was therefore unclear whether tau aggregation played a role as a causative agent
in neuronal cell death or was simply a byproduct of other toxic mechanisms. The potential
for a causative role was greatly strengthened with the identification of a group of mutations
in the tau gene that led to early-onset frontotemporal dementias (20, 21). Many of the
mutations cause increased propensities for aggregation and decreased microtubule
interactions which could represent toxic gain and loss of functions respectively (13, 22–31),
Several of the mutations have also been utilized in a diverse set of model organisms,
including nematodes, flies, Xenopus, and mice ((25, 32–35), reviewed in (36)). These
naturally-occurring mutations have provided an invaluable tool to the study of tau
aggregation, but their effects have not always been consistent across the spectrum of
mutants or model organisms (37).
It is possible that some of the observed differences in the effects of tau aggregation in
cellular and animal models are a direct result of the various FTDP-17 mutations employed to
generate aggregated tau. Certain FTDP-17 mutations have been shown to increase the rate or
total amount of tau aggregation both in vitro and in vivo which may be leading to early-
onset tauopathies (22, 26, 34, 38, 39); some FTDP-17 mutants show decreased binding to
microtubules and an impaired ability to stabilize polymerization of tubulin while others have
little effect (23, 40). In addition, the progression and pathologies of FTDP-17 can vary
greatly depending on the specific mutation, indicating that initial causes of the disease may
vary as well (reviewed in (41)). We therefore sought to compare several FTDP-17 mutations
under the same conditions to determine how they affected aggregation and microtubule
interaction, two factors that may have causative roles in the toxicity of these diseases, and
whether differences in the intrinsic effects of FTDP-17 mutations could be correlated to
these changes. From the 25 known FTDP-17 missense mutants of tau, we chose to model the
12 mutations predicted to have the most significant impact on tau charge, hydrophobicity
(42) and structure (43). Our predictions were based on an analysis demonstrating that these
parameters were the primary determinants of aggregation rates (44). We chose to model
these mutants in the background of full-length 2N4R tau in vitro to provide direct side-by-
side comparisons to assess the impact of the structural modifications.
We found that the FTDP-17 mutants had very different effects on the aggregation and
microtubule interactions of tau. These changes in aggregate amounts, rates and
morphologies could help in our understanding of the varied pathologies and toxicities
resulting from the mutations. While some of the mutations had similar effects on tau
function and aggregation, we found that there was not a simple correlation between the
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effects on tau and the protein’s charge, hydrophobicity or predicted structure. This indicates
that predictive methods are insufficient for determining the impact of tau mutations on the
severity of impairment.
EXPERIMENTAL PROCEDURES
Selection of FTDP-17 mutations
Mutations were selected based on their predicted changes to average hydrophobicity, charge,
α-helical structure, β-strand structure, and turns. These predictions were calculated across 7
amino acid-long sequences for the entire 2N4R tau isoform using Kyte-Doolitte values to
estimate hydrophobicity (42) and Chou-Fassmann parameters for effects on secondary
structure (43). The effect of each mutant was ranked according to each of these factors and
the total effect was estimated based on summation of rankings for each variant. The 11
mutants predicted to have the largest effects on the structure of the protein were chosen
along with V337M, a mutant commonly used to generate tau aggregation in in vivo models.
Protein expression and purification
All wild-type (WT) and FTDP-17 mutant protein was expressed and purified as described
previously (45). The FTDP-17 mutations were created using the Quikchange site-directed
mutagenesis kit from Stratagene (La Jolla, CA). The following mutations were generated in
a full-length 2N4R tau background contained in a pT7C vector: R5L, G272V, ΔN296,
P301L, G303V, L315R, S320F, V337M, E342V, S352L, K369I, and G389R.
Arachidonic acid-induced polymerization
Recombinant WT and mutant tau protein, at a concentration of 2 μM, was incubated in
buffer containing 0.1 mM EDTA, 5 mM dithiothreitol, 10 mM Hepes buffer (pH 7.64), 100
mM NaCl, and 3.75% ethanol in a 1.5 mL microcentrifuge tube. The polymerization inducer
molecule was arachidonic acid (ARA) at a concentration of 75 μM. Reactions were allowed
to proceed overnight at 25 °C.
Thioflavin S fluorescence
The total amount of aggregation was measured utilizing the binding of thioflavin S (ThS)
from Sigma-Aldrich (St. Louis, MO). 150 μL of each reaction was added to separate wells
in a 96-well, white, flat-bottom plate. ThS was diluted in water and added to the well to a
final concentration of 20 μM. The fluorescence shift was measured by using a Cary Eclipse
Fluorescence Spectrophotometer (Varian Analytical Instruments, Walnut Valley, CA) with
an excitation wavelength of 440 nm and an emission wavelength of 520 nm. PMT voltage
was set to 650 V. Readings from a reaction with 2 μM protein and 0 μM ARA were used as
a blank and subtracted from the reading for each reaction (45).
Right-angle laser light scattering
Aggregation of the protein was also read by adding 180 μL of the reaction to a 5 mm × 5
mm optical glass fluorometer cuvette (Starna Cells, Atascadero, CA). A 12 mW solid state
laser, with a wavelength of λ=532 nm and operating at 7.6 mW, was aimed at the cuvette.
The amount of light scattered by particles in the reaction was measured by capturing the
amount of light perpendicular to the angle of the beam using a SONY XC-ST270 digital
camera. The images were captured at varying aperture settings (from f4 to f11) and analyzed
using the histogram function of Adobe Photoshop CS5 version 12.0.1. (25).
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ARA was added to our polymerization buffer (0.1 mM EDTA, 5mM dithiothreitol, 10 mM
Hepes buffer (pH 7.64), 100 mM NaCl) to a final concentration of 75 μM and 3.75%
ethanol in a 5 mm × 5 mm optical glass fluorometer cuvette. Tau polymerization was
measured by collecting images of the right-angle scattered light at specific time points
beginning from the initiation of the reaction upon addition of protein, at a final concentration
of 2 μM, and the ending once the reaction had reached a steady-state. The data were fit to
the Finke-Watzky 2-step mechanism, designed to describe the nucleation and elongation of
protein aggregation (46). The mechanism assumes simplified nucleation  and
elongation  steps to yield the following equation:
The k1 and k2 rate constants are used to qualitatively compare the rates of nucleation and
elongation, respectively, of our protein aggregation reactions.
Transmission electron microscopy
The ARA-induced polymerization reactions were diluted 1:10 in polymerization buffer and
2% glutaraldehyde. After a five minute incubation, a formvar-coated copper grid (Electron
Microscopy Sciences, Hatfield, PA) was placed on top of a 10 μL drop of the diluted sample
for 1 minute. The grid was then blotted on filter paper, placed on a drop of water, blotted
with filter paper, placed on a drop of 2% uranyl acetate, and blotted dry. The grid was then
placed on another drop of 2% uranyl acetate for 1 minute and blotted dry for a final time.
For all tau variants a single grid was prepared and examined from each of three separate
reactions. The grids were examined using a TECNAI G2 20 electron microscope (FEI Co.,
Hillsboro, OR). Images were collected with the Gatan Digital Micrograph imaging system at
a magnification of 3600X. Five images were collected from each grid and analyzed. The
aggregated tau in each of the 15 images was quantified by using Image-Pro Plus 6.0. The
macro was designed to recognize filaments with a total perimeter of greater than 30 nm.
This captured what we felt to be legitimate aggregates while eliminating background noise.
The perimeter of each filament was measured and divided by two in order to estimate the
filament’s length. These values were totaled in order to estimate the total amount of
aggregated material in each image. The total polymerization/image was calculated by taking
the mean of all total polymerization values. The mean of all filament lengths was also
determined by calculating the mean length of all filaments in a given image and reported as
a mean of those values with the error bars representing standard deviation.
Tubulin polymerization assay
The Tubulin Polymerization Assay kit from Cytoskeleton, Inc. (Denver, CO) was used to
measure the polymerization of tubulin. The reaction conditions included WT tau or one of
the tau variants at 1 μM, or a control compound, added along with 1 mM GTP, 2 mg/ml
(~36 μM dimerized) tubulin, 2 mM MgCl2, and 0.5 mM EGTA in 80 mM PIPES buffer at a
pH of 6.9. The reaction proceeded in a black, flat-bottomed polystyrene 96-well plate.
Paclitaxel was used at 3 μM in one reaction to serve as a positive control for tubulin
polymerization, as well as a way to normalize separate reactions. One well contained no
additional compound as a negative control. After addition of the compounds the plate was
inserted into a FlexStation II Fluorometer (Molecular Devices Corporation, Sunnyvale, CA)
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set at a temperature of 37 °C and the reactions were mixed by shaking for 5 seconds. The
fluorescence was measured with an excitation wavelength of 355 nm and an emission
wavelength at 455 nm at 1 minute intervals for 1 hour. The data were fit to the Gompertz
equation
as described earlier (47, 48). The maximum amount of tubulin polymerization is described
by a, the lag time from reaction initiation to the start of polymerization is ti – b, and kapp, or
1/b, is proportional to the rate of polymerization.
Statistical analysis
An unpaired two-tailed Student’s t-test was used to compare means of WT values to mean
values of each mutant for thioflavin S fluorescence, right-angle laser light scattering,
quantitative electron microscopy, and kinetics parameters. A paired two-tailed t-test was
used to compare the values for the microtubule assembly assay. P-values less than or equal
to 0.05 were indicated with one asterisk (*), less than or equal to 0.01 with two asterisks
(**), and less than or equal to 0.001 with three asterisks (***). Because variation among the
mutants is also important to consider, statistical variation in the entire groups was measured
by using a one-way ANOVA analysis with a Tukey’s Multiple Comparison test and
compiled in tables included in supplemental information. The p-values for this comparison
were also indicated using the asterisk system described above.
RESULTS
Selection of FTDP-17 mutations
A list of 25 known FTDP-17 mutations was generated and ranked based on the total
predicted changes to the structure of the protein. The 11 mutations predicted to induce the
largest structural changes were selected along with V337M which was selected because it
has previously been used in several model organisms. The majority of the chosen FTDP-17
mutations can be found within, or very near to, one of the 4 MTBR while R5L and G389R
are found in the N- and C-terminal regions respectively (Figure 1).
FTDP-17 mutations induce varying effects on total polymerization
In vitro experiments were used to examine the effects of the 12 mutations on the ARA-
induced polymerization of tau at 2 μM protein and 75 μM ARA (49). After the reactions
proceeded overnight, the total amount of aggregation was measured by ThS fluorescence
and right-angle laser light scattering (LLS). Half of the mutant proteins displayed an
increase in ThS fluorescence compared to WT tau protein (G272V, P301L, G303V, S320F,
S352L and G389R), indicating that more protein had polymerized in those reactions. Others
had levels of polymerization that were similar to WT tau (R5L, ΔN296, V337M and
E342V), while two of the mutants showed a clear decrease (L315R and K369I) (Figure 2A).
LLS can be used as another method to measure relative amounts of protein aggregation (25).
However, in this case the results differed from those found in ThS fluorescence. Only three
mutants showed a clear increase over WT (R5L, P301L and S352L), while five of the
mutants showed a decrease in scattered light (G272V, G303V, L315R, S320F and K369I)
and four mutants had levels similar to WT (ΔN296, V337M, E342V and G389R) (Figure
2B). Results from one-way ANOVA analyses with Tukey’s multiple comparison tests can
be found in Supplemental Tables 1 and 2. This analysis demonstrates that not only are many
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of the mutants different from WT, but there is also a wide range in variation between
mutants as well.
FTDP-17 mutations induce varying effects on aggregate morphology
Because LLS is known to be affected by the length distribution of the aggregates (25) and
the structure of tau recognized by ThS is unknown (16, 50), the aggregates of tau were
viewed directly by electron microscopy (Figure 3). Direct visualization of the aggregates can
help in elucidating some causes of the apparent variation between the ThS and LLS results
(Figure 2). WT tau displays a characteristic mixture of longer filaments and smaller
aggregates less than 100 nm in length, hereafter described as oligomers (Figure 3A).
Examination of the images made it abundantly clear that the mutations were inducing very
different effects on the aggregation of the protein. Some of the mutants, such as G303V and
S320F are almost entirely made up of oligomers (Figures 3F and H). Others, including R5L,
S352L, and P301L seem to be lacking oligomers and display longer filaments than WT tau
(Figures 3B, E, and K). Very few aggregates were associated with K369I which confirms
earlier ThS and LLS results (Figures 2 and 3L). We next sought to determine if the apparent
differences we observed could be detected by quantitative methods and whether these
differences were significant. To accomplish this we measured the number and length of
filaments displayed in five representative images from each of three different reactions for
each tau variant.
Quantitation of the total amount of aggregated material indicated that most of mutant forms
of tau variants polymerized to a similar extent as WT tau but images from G303V, S320F,
and E342V all contained more total polymerized tau than WT (Figure 4A). In contrast,
K369I and G389R displayed less polymerization than WT in these images. K369I had
considerably fewer aggregates than WT and these aggregates were very short in nature and
in general did not stain as intensely as tau aggregates associated with WT and the other
mutants, again indicating low levels of polymerization (Figures 3L and 4B).
The differences in aggregation, apparent in Figure 3, were confirmed by comparing the
average lengths of all filaments for each tau variant. Several mutants (G272V, G303V,
L315R, S320F, and G389R) displayed shorter average filament lengths while filaments from
R5L, P301L, and S352L were much longer on average than WT (Figure 4B). Average
filament lengths are not amenable to statistical analysis due to their exponential distribution.
Therefore, the data from each of the 15 electron micrographs were plotted as average
filament length versus the number of filaments formed to demonstrate the variation in the
data (Supplemental Figure 1). These plots also supported the differences in filament
morphology described above. Further variation can be observed by determining how much
of the total polymerization is due to very short filaments. We calculated the percent of the
total polymerized material that was made up of filaments shorter than 100 nm (Figure 4C).
Around 30% of polymerized WT tau was contained in short filaments while oligomers made
up greater than 90% of the total for G303V, S320F, and K369I. Others, such as R5L,
ΔN296, P301L, and S352L, again induced a very different effect and contained much lower
percentages, indicating that longer filament lengths and fewer oligomers were present
(Figure 4C).
In light of the quantitative EM data, the discrepancy between ThS fluorescence and LLS
measurements of tau mutant aggregation is likely due to the disparate morphologies of the
resulting filaments. In fact, there is a direct correlation between filament length, as measured
through electron microscopy (Figures 3 and 4B), and the ratio of ThS fluorescence to LLS
values (Supplemental Figure 2). Therefore, the amount of light scattering from two
populations of filaments of very different length distributions may not be equally
proportional to the mass of filaments.
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Kinetics of polymerization varies by FTDP-17 mutant
Because the morphology of tau aggregates can be influenced by the rate of polymerization
(49), we sought to determine whether the mutations were affecting the kinetics of
polymerization. Polymerization reactions for each mutant were followed by LLS and were
then fit to a two-step model of polymerization to determine nucleation and elongation rates
(Figure 5). The K369I mutant had nearly undetectable levels of polymerization in this assay
and could therefore not be fit to the model.
A visual inspection of the curves indicated a wide range of polymerization kinetics between
mutants (Figure 5). A comparison of nucleation rates (k1, Figure 6A) indicated that G272V,
G303V, L315R, and S320F had significantly increased nucleation rates as compared to WT
while R5L, P301L, E342V, and S352L had significantly decreased nucleation rates (Figure
6A). G303V, L315R and S320F also had greatly reduced elongation rates as compared to
WT (k2, Figure 6B), such that the elongation phase was essentially undetectable. E342V and
S352L had elongation rates that were significantly reduced compared to WT but elongation
was still detectable (Figure 6B). The only mutant with a faster elongation rate than WT was
P301L (Figure 6B). In addition to these differences from WT protein, further analysis of the
data using one-way ANOVA with Tukey’s multiple comparison tests demonstrates that
many of the mutants are significantly different from one another. For example, the kinetics
of elongation (k2) of the P301L mutant is significantly different from G303V, L315R,
S320F, V337M, S352L and G389R (Supplemental Tables 3 and 4).
FTDP-17 mutations can inhibit ability of tau to stabilize microtubule assembly or have little
effect
We then sought to determine whether the FTDP-17 mutations would have differential
effects on one of tau’s normal functions of stabilizing microtubules. Microtubule
polymerization was monitored using a fluorescence based assay and the resulting curves
(Supplemental Figure 3) were fit to a Gompertz function in order to determine maximal
extent of microtubule polymerization, the rate of elongation, and lag time in the presence of
the FTDP-17 mutants (Figure 7). Most proteins stabilized microtubules to similar levels as
WT tau, but G303V, L315R, and S352L did not (Figure 7A). P301L, G303V, S320F, and
S352L induced microtubule elongation at a slower rate while V337M and E342V actually
increased the rate of tubulin polymerization (Figure 7B). The lag time for tubulin
polymerization was decreased in the presence of G272V, L315R, V337M, E342V, and
G389R but increased in the presence of G303V and S352L (Figure 7C). In addition to these
differences in FTDP-17 mutants as compared to WT, results from one-way ANOVA
analyses with Tukey’s multiple comparison tests demonstrate that there were many
statistically significant differences between FTDP-17 mutants as well (Supplemental Tables
5–7).
DISCUSSION
FTDP-17 mutations in tau are extremely rare but play a particularly important role in the
study of tau aggregation associated with familial and sporadic tauopathies. Some of these
mutations are commonly used in disease models in order to enhance protein aggregation.
However, among the FTDP-17 mutants there exists significant variability in symptoms and
pathology of diseases, indicating that there may be differing root causes of the disease.
While most known mutations are found within one of the four MTBRs, the locations vary
from the N- to the C-terminal regions. The amino acid substitutions or deletions result in
increased or decreased hydrophobicity and charge, as well as induce a variety of potential
changes in the transient secondary structure of the protein. In addition, other factors such as
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alterations in splicing or phosphorylation pattern could be playing a major role in the
neurodegenerative process.
Because of the differences in pathology of aggregation and disease progression, it is
important to determine how the mutations are changing the properties of the tau protein as
well as how these changes could be affecting the associated neurodegeneration patterns.
Previous work has shown that the rate of tau aggregation into amyloid could be predicted by
calculating expected changes in hydrophobicity, charge, and secondary structure due to three
known FTDP-17 mutations (44). In addition, other studies have examined the in vitro
properties of small numbers of known mutants (22, 25, 26). We sought to directly compare
aggregation and function of WT and a wider variety of FTDP-17 mutant forms of tau under
similar conditions, using the same mechanisms for inducing aggregation, as well as to
determine whether these predictive tools would apply to an expanded field of mutations.
After studying the effects of FTDP-17 mutations on the in vitro aggregation of tau and its
microtubule-stabilization properties we determined that the mutants had very distinct
profiles from WT tau as well as each other. We were able to group some of the mutants
together based on their common properties and speculate on some of the causes for these
general trends although we could not detect a clear pattern between the effects in these
assays and the intrinsic changes predicted to occur due to mutations. Some of the mutations
induced similar effects on filament morphology that may be tied to their aggregation
kinetics, but the overall trends pointed to large differences in the behavior of the mutated
versions of tau in our assays.
Several of the mutants displayed shorter average filament lengths than WT which seemed to
be due to an increase in the number of oligomers and a decrease in the length and number of
longer filaments. The increase in the number of oligomers from this group may be explained
by the increased rate of nucleation that was also associated with these four mutations. Fast
nucleation would take up large amounts of monomeric tau quickly and drop the protein level
below the critical concentration of aggregation before elongation could begin. Interestingly,
four of the mutations with decreased filament length occur directly before and after
the 275VQIINK and 306VQIVYK sequences, important for aggregation of tau, and may be
causing increased nucleation through enhancements of the β-strand character (11, 51).
G272V, G303V, and S320F are predicted to enhance β-strand structure and extension of the
β-strands in these regions has been shown to enhance polymerization in other mutants,
although with slightly different effects (52). The fourth mutation, L315R, is not predicted to
enhance β-strand character, but it would replace a hydrophobic amino acid with a positive
charge on the polar/charged side of an amphipathic β-strand which may help promote the
cross-β amyloid structure (52). Strengthening the β-strand secondary structure in these key
regions may increase nucleation; making it more likely that tau will begin to aggregate,
leaving little tau left for the elongation phase of polymerization. Therefore the rate of
nucleation is an important determinant of the ratio of oligomers to fibrils formed under these
conditions.
Another group of mutations induced the opposite effects on the filament morphology
phenotype. R5L, P301L, and S352L all induced fewer, but longer filaments, than WT or the
other mutant versions of tau. These were slower to nucleate than WT tau which could be
another indication of the importance of nucleation rate on filament morphology. Despite the
similarities in the rates of nucleation, the elongation rates of these three tau mutants varied
widely compared to WT; R5L was similar, P301L was faster, and S352L was slower. Even
though each of these mutants aggregated into long filaments with few oligomers, the
mechanisms of aggregation were quite dissimilar.
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It may seem unusual that R5L, a mutation that is far away from the MTBR, would have such
large effects on the aggregation of the protein but the N-terminal region has been shown to
have an enhancing effect on aggregation which may be due to alterations in the global
hairpin conformation (38, 53, 54). The P301L mutation is much closer to the 306VQIVYK
hexapeptide than R5L and the removal of a proline in the PGGG sequence preceding it
could assist in the formation of a β-strand in such a way as to stabilize the formation of
longer filaments with an altered morphology (55). S352L also enhances the β-strand
character around the 350VQLKI sequence which is very similar to the 275VQIINK
and 306VQIVYK sequences that form the amphipathic β-strands crucial for the formation of
tau filaments. The addition of another amyloidogenic sequence could assist in stabilizing
longer filaments.
While the mutants discussed above had obvious effects on the morphology of the
aggregates, other mutants, such as ΔN296, V337M, and E342V, displayed aggregates that
were much more similar to WT protein. These mutants aggregated into mixes of short and
long filaments with roughly the same number of filaments as WT tau. These mutations are
further from the 275VQIINK and 306VQIVYK sequences and may not have as strong of
effects on those regions even if they are enhancing the β-strand character around them.
These minor changes may indicate that the root causes of these tauopathies may lie
somewhere other than direct increases in tau aggregation. For example, the N296 position is
also associated with other FTDP-17 mutations that can lead to splicing defects and V337M
can lead to increased phosphorylation ((31) and reviewed in (56)).
While general trends in the aggregation of mutated proteins could be identified, the
interactions with microtubules followed an alternate pattern. Only mutations that occur
within one of the 18 amino acid repeats in the MTBR displayed effects on the ability of the
protein to stabilize assembly of microtubules, confirming previous results with other
FTDP-17 mutations (57). Of the mutants that fell outside of the MTBR or in one of the
interrepeats (R5L, L315R, V337M, E342V, K369I, and G389R) only L315R displayed any
decrease from WT tau in the total amount of microtubule polymerization. This was a
relatively minor change compared to the effects of the other mutants and was in agreement
with previous results (58). All of the mutants located within one of the repeat regions were
unable to stabilize the same maximum level of microtubule polymerization, stabilized a
slower rate of polymerization, or altered the lag time compared to WT tau. These results,
combined with the large percentage of FTDP-17 mutations located in a MTBR, indicate that
interactions with microtubules may play a key role in the progression of these tauopathies.
Further research is needed to determine how altered microtubule interactions may be
affecting tau aggregation as well as if affected microtubule dynamics may be playing a more
direct role in toxicity.
Direct comparisons of our results to previous studies can be difficult due to differing
experimental setup. The most common differences involve the type of tau aggregation
inducer employed, the buffer conditions, and the tau isoform used in the assays. Our data
confirm previous results indicating that P301L is a very fast aggregator compared to WT,
several of these FTDP-17 mutants have decreased abilities to stabilize assembly of
microtubules and increased aggregation, and K369I typically forms smaller aggregates (25,
59–61). Occasionally, differences were seen in the kinetics of aggregation that may be
ascribed to how the data are measured and what type of curve they are fit to. We feel that the
Finke-Watzky mechanism is best able to describe the complex process of tau aggregation in
a simplified manner and accurately represented differences in the mechanisms of
aggregation for the studied mutations.
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The fact that significant differences exist in how these mutants aggregate, the types of
aggregates that are seen, as well as their ability to perform normal functions of tau in vitro
should not be particularly surprising given the diversity in disease phenotype associated with
FTDP-17 cases and tauopathies in general. Conformational differences among the mutations
are likely to affect the protein’s aggregation in complex ways which could then have a direct
impact on disease progression. These differences could manifest themselves in the initiation,
morphology, or spread of aggregation. While the end result may always be aggregation of
tau and degeneration of neurons, the mechanisms by which the various diseases reach that
point may be drastically different and alternate therapeutic interventions may be required
based on the initiating cause of the disorder. As it is likely that sporadic tauopathies also
differ in their initiating factors, information about how certain FTDP-17 mutations affect tau
may be applicable to the progression of those diseases as well.
In order to attempt to explain some of these initiating factors we attempted to find
correlations between the intrinsic effects of our chosen mutations and their effects on tau in
our various assays. However, we were unable to detect any correlations among these
components. It is likely that these effects are complicated and dependent on the specific
location of the mutation.
Given the importance of the MTBR in the function and dysfunction of tau, it is likely that
location is a very important factor for how these mutations are affecting the aggregation of
the protein. Mutations that increased the hydrophobicity and β-strand character, especially in
the MTBR, seem to increase the rate of nucleation and decrease the average filament length
but exceptions to this exist as well. The causes of familial tauopathies are likely quite
complex. Mutation-induced effects on intrinsic properties of tau may alter its propensity for
aggregation or the morphology of its aggregates and lead to early-onset tauopathies.
However, changes in mRNA splicing, interactions with microtubules, or phosphorylation
levels could also lead to aggregation of the protein or neuronal death. In addition, the
mutations could also affect other properties of the protein including interactions with protein
degradation systems, kinases, or fast axonal transport among others.
Because of the variation in location and effects on intrinsic properties of tau, significant
differences exist in how FTDP-17 mutations affect the protein. While these mutations can be
quite useful for in vitro and in vivo models of tau aggregation and tauopathies, it may be
important to consider the differential effects when comparing results from various model
systems. Further work on characterizing these mutations and their effects on in vivo
organisms may help explain how the various FTDP-17 mutations are leading to tauopathies
and how these mechanisms are affecting our understanding of the progression of sporadic
tauopathies.
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Figure 1. Schematic of FTDP-17 mutations in 2N4R tau
Each of the naturally-occurring FTDP-17 mutations indicated in the figure was created in a
full-length 2N4R tau background. E2, E3, and E10 represent exons that can be excluded
from other tau isoforms. Regions known to exhibit transient secondary structure are
indicated by cylinders (α-helices) or arrows (β-strands). Boxes R1-R4 represent
microtubule-binding repeat regions.
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Figure 2. Polymerization of wild-type and FTDP-17 mutant tau measured by thioflavin S
staining and right-angle laser light scattering
Polymerization reactions contained 2 μM of WT or one of 12 FTDP-17 mutant versions of
tau and 75 μM ARA. Reactions were incubated overnight at 25° C. The final extent of
polymerization was measured by (A) ThS fluorescence and (B) right-angle LLS as described
in the Experimental Procedures. Data represent the mean from 3 experiments ±SD. Stars
represent p-value results from Student’s unpaired t tests comparing means from each mutant
to WT. (*), p < 0.05; (**), p < 0.01; (***), p < 0.001. More extensive statistical analysis can
be found in Supporting Materials.
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Figure 3. Electron micrographs of polymerization reactions containing 2 μM protein and 75 μM
ARA
A representative electron micrograph for (A) WT tau, (B) R5L, (C) G272V, (D) ΔN296, (E)
P301L, (F) G303V, (G) L315R, (H) S320F, (I) V337M, (J) E342V, (K) S352L, (L) K369I,
and (M) G389R. The scale bar in (M) represents 1 μm and is applicable for all images.
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Figure 4. Quantitation of polymerized tau protein in electron micrographs
Images in the electron micrographs from Figure 3 were quantified using Image-Pro Plus 6.0
as described in the Experimental Procedures. The graphs display (A) the mean of the total
length (μm) of polymerized tau filaments/image, (B) the mean length of filaments (nm), and
(C) the percent of the total length coming from filaments less than 100 nm in length for each
of the tau variants. Data in (A) represent the mean of 5 images from each of 3 separate
reactions ±SD for a total of n=15. Data in (B) represent the means of the mean filament
length for each of the 15 images ±SD. Data in (C) represent means of the sum of all filament
lengths less than 100 nm as a percent of the total length for each image ±SD, n=15. Stars
represent p-value results from Student’s unpaired t tests comparing means from each mutant
to WT. (*), p < 0.05; (**), p < 0.01; (***), p < 0.001.
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Figure 5. Kinetics of tau polymerization
Polymerization reactions containing 2 μM tau were initiated by the addition of 75 μM ARA.
LLS readings were measured at specific time intervals until the reactions reached a steady-
state. The traces here represent mean values ±SD from 3 reactions fit to the Finke-Watzky
mechanism described in the Experimental Procedures and displayed over 250 minutes for
WT tau protein (light gray) and various FTDP-17 mutant tau protein (black) including (A)
R5L, (B) G272V, (C) ΔN296, (D) P301L, (E) G303V, (F) L315R, (G) S320F, (H) V337M,
(I) E342V, (J) S352L, and (K) G389R.
Combs and Gamblin Page 19










Figure 6. Comparison of tau polymerization kinetics
The parameters describing the tau polymerization kinetics curves fit to the Finke-Watzky
mechanism are displayed. The first parameter is (A) k1, representing the rate of nucleation
or formation of oligomers. The second parameter is (B) k2, the rate of elongation or
extension of the oligomeric tau aggregates into filaments. Data represent means of values for
fits of at least 3 separate reactions ±SD. Stars represent p-value results from Student’s
unpaired t tests comparing means from each mutant to WT. (*), p < 0.05; (**), p < 0.01;
(***), p < 0.001. More extensive statistical analysis can be found in Supporting Materials.
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Figure 7. Stabilization of microtubule assembly by tau protein
The tau variants were incubated with tubulin and its polymerization was measured via a
fluorescence assay. Numbers were normalized to values of polymerization in the presence of
paclitaxel. The relative fluorescence units (y-axis) were plotted vs. time (x-axis) and fit to
the Gompertz equation as described in the Experimental Procedures. From the parameters
describing these curves, the percent of WT values for the (A) maximum amount of
microtubule polymerization in presence of each protein, (B) kapp or rate of microtubule
polymerization, and (C) lag time, the time before microtubule polymerization is detected.
The values in (A–C) are mean values of the percent changes from WT in three separate
experiments ±SD. Stars represent p-value results from Student’s paired t tests comparing
means from each mutant to WT. (*), p < 0.05; (**), p < 0.01; (***), p < 0.001. More
extensive statistical analysis can be found in Supporting Materials.
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